Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
Titel:
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
Auteur:
Wang, Zhijie Cheng, Ying An, Tongtong Gao, Hongjun Wang, Kai Zhou, Qing Hu, Yanping Song, Yong Ding, Cuimin Peng, Feng Liang, Li Hu, Yi Huang, Cheng Zhou, Caicun Shi, Yuankai Zhang, Li Ye, Xin Zhang, Meizhuo Chuai, Shaokun Zhu, Guanshan Hu, Jin Wu, Yi-long Wang, Jie